Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA

被引:101
作者
Porter, KE
Turner, NA
O'Regan, DJ
Balmforth, AJ
Ball, SG
机构
[1] Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England
[2] Gen Infirm, Yorkshire Heart Ctr, Dept Cardiac Surg, Leeds LS1 3EX, W Yorkshire, England
关键词
statins; cardiac fibroblasts; human; cell proliferation; remodeling; RhoA; Cyclin A;
D O I
10.1016/j.cardiores.2003.11.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Adverse atrial and ventricular myocardial remodeling is characterized by fibrosis, myocyte death or hypertrophy and fibroblast proliferation. HMG-CoA reductase inhibitors (statins) are widely prescribed cholesterol-lowering drugs that also appear to have beneficial effects on myocardial remodeling. Although statins are known to reduce myocyte hypertrophy, their effect on cardiac fibroblast proliferation is unknown. The purpose of this study was to investigate the effects of simvastatin on human atrial myofibroblast proliferation. Methods: Cardiac myofibroblasts were cultured from biopsies of human right atrial appendage. Proliferation was quantified by cell counting and cell cycle progression determined by immunoblotting for Cyclin A. The expression, activation and intracellular localization of RhoA were investigated using immunoblotting and immunocytochemistry. Results: Simvastatin (0.1 - 1.0 mumol/l) inhibited serum-induced myofibroblast proliferation in a concentration-dependent manner at a point upstream of Cyclin A expression. These effects were reversed by mevalonate or geranylgeranyl pyrophosphate (GGPP), but not squalene or farnesyl pyrophosphate (FPP), indicating a mechanism involving inhibition of Rho-family GTPases and independent of cholesterol synthesis. The effects of simvastatin were mimicked by inhibiting Rho geranylgeranylation or Rho-kinase activation. Furthermore, we demonstrated that simvastatin inhibited RhoA function by preventing its association with the plasma membrane and hence, its interaction with downstream effectors required for cell proliferation. Conclusions: Simvastatin reduced proliferation of cultured human atrial myofibroblasts independently of cholesterol synthesis via a mechanism involving inhibition of RhoA geranylgeranylation. Statins may therefore have an important role in preventing adverse myocardial remodeling associated with cardiac myofibroblast proliferation. (C) 2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:745 / 755
页数:11
相关论文
共 44 条
[1]   Characterization of adult human heart fibroblasts in culture: A comparative study of growth, proliferation and collagen production in human and rabbit cardiac fibroblasts and their response to transforming growth factor-beta(1) [J].
Agocha, A ;
Sigel, AV ;
EghbaliWebb, M .
CELL AND TISSUE RESEARCH, 1997, 288 (01) :87-93
[2]   Electrical, contractile and structural remodeling during atrial fibrillation [J].
Allessie, M ;
Ausma, J ;
Schotten, U .
CARDIOVASCULAR RESEARCH, 2002, 54 (02) :230-246
[3]  
Allessie MA, 2001, CIRCULATION, V103, P769
[4]   Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction [J].
Bauersachs, J ;
Galuppo, P ;
Fraccarollo, D ;
Christ, M ;
Ertl, G .
CIRCULATION, 2001, 104 (09) :982-985
[5]   Is angiotensin II a proliferative factor of cardiac fibroblasts? [J].
Bouzegrhane, F ;
Thibault, G .
CARDIOVASCULAR RESEARCH, 2002, 53 (02) :304-312
[6]   Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling [J].
Cohn, JN ;
Ferrari, R ;
Sharpe, N .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (03) :569-582
[7]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[8]   Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines:: an in vitro study [J].
Denoyelle, C ;
Vasse, M ;
Körner, M ;
Mishal, Z ;
Ganné, F ;
Vannier, JP ;
Soria, J ;
Soria, C .
CARCINOGENESIS, 2001, 22 (08) :1139-1148
[9]  
EGHBALI M, 1992, BASIC RES CARDIOL, V87, P183
[10]  
FALK H, 1982, BILIRUBIN, V1, P7